Chris Liang

Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase

Li Sun, Chris Liang, Sheri Shirazian et al. · Journal of Medicinal Chemistry · 2003 · 518 citations · Full text

Chemoprevention Strategy, Weakly Basic Analogues, Pharmacotherapy +20

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Leora Horn, Ziping Wang, Gang Wu et al. · JAMA Oncology · 2021 · 228 citations · Full text

Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

Christine M. Lovly, Johannes M. Heuckmann, Elisa de Stanchina et al. · Cancer Research · 2011 · 214 citations · Full text

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Leora Horn, Jeffrey R. Infante, Karen L. Reckamp et al. · Clinical Cancer Research · 2018 · 188 citations

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

Leora Horn, Jennifer G. Whisenant, Heather A. Wakelee et al. · Journal of Thoracic Oncology · 2019 · 158 citations · Full text